Cerevel Therapeutics Holdings Inc (CERE)

Finanzdaten der Cerevel Therapeutics Holdings Inc-Aktie (CERE)

Gewinn- und Verlustrechnung

Vierteljährlich

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	-	-	-	-	-3.668
Operating Expenses	25.39% 139.56	111.31	96.84	99.55	107.25
Interest Income/Expense	0.11% 2.647	2.644	2.64	2.636	2.632
Operating Income/Loss	25.39% -139.56	-111.31	-96.84	-99.55	-107.25
Income/Loss From Continuing Operations Before Tax	37.65% -132.47	-96.24	-99.43	-104.20	-92.65
Income Tax Expense/Benefit	52.85% 0.188	0.123	0.107	0.085	-
Income/Loss From Continuing Operations After Tax	37.67% -132.66	-96.36	-99.53	-104.29	-92.81
Net Income/Loss	37.67% -132.66	-96.36	-99.53	-104.29	-92.81
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	96.83% 4.9873	157.50	157.05	156.65	1.7214
Diluted Average Shares	96.83% 4.9873	157.50	157.05	156.65	1.7214
Basic Earnings Per Share	24.59% -0.76	-0.61	-0.63	-0.67	-0.59
Diluted Earnings Per Share	24.59% -0.76	-0.61	-0.63	-0.67	-0.59
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-